The activation of EGFR in tumor cells can modulate the expression of many genes in downstream signaling pathways to inhibit the migration, recognition, and killing of immune cells, thereby facilitating immune evasion by tumor cells and diminishing the efficacy of immunotherapy. This evidence concerns the gene EGFR and neoplasm.